SBI Securities’s Moleculin Biotech MBRX Stock Holding History

SBI Securities’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$17	Hold	2	–	–	﹤0.01%	3943
2026 Q2	$123	Hold	2	–	–	﹤0.01%	3463
2026 Q1	$98	Buy	2 +1	+100%	+$66	﹤0.01%	3414
2025 Q4	$96	Hold	1	–	–	﹤0.01%	3417
2025 Q3	$395	Hold	1	–	–	﹤0.01%	3068
2025 Q2	$225	Hold	1	–	–	﹤0.01%	3270
2025 Q1	$726	Hold	1	–	–	﹤0.01%	2725
2024 Q4	$689	Buy	+1	New	+$1.21K	﹤0.01%	2769

Other funds holding MBRX

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

SBI Securities's MBRX Position: Q3 2026 in Review

SBI Securities held its Moleculin Biotech (MBRX) position steady in Q3 2026 at 2 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #3943.

SBI Securities first reported a position in MBRX in Q4 2024 and has held it in 8 quarters since. The position peaked at $726 in Q1 2025. 2 funds tracked by Wall St. Rank hold MBRX as of Q3 2026.

SBI Securities held 2 shares of Moleculin Biotech worth $17 as of Q3 2026.
SBI Securities left its Moleculin Biotech share count unchanged in Q3 2026.
Moleculin Biotech made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3943 holding.
SBI Securities first reported a position in Moleculin Biotech in Q4 2024 and has held it in 8 quarters since.
SBI Securities's Moleculin Biotech position peaked at $726 in Q1 2025.
2 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.